Inhibition of TGFβ signaling in cancer therapy

被引：106

作者：

Arteaga, CL ^{[1
]}

机构：

[1] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Breast Canc Res Program, Nashville, TN 37212 USA

[2] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Canc Biol,Breast Canc Res Program, Nashville, TN 37212 USA

来源：

CURRENT OPINION IN GENETICS & DEVELOPMENT | 2006年 / 16卷 / 01期

关键词：

D O I：

10.1016/j.gde.2005.12.009

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Recent evidence continues to support a central role for TGF beta in tumor maintenance and progression. Although this may involve TGF beta-mediated paracrine effects that modulate the tumor microenvironment and the host immune system, some studies causally implicate autocrine TGF beta in cancer cell motility and survival. Other recent evidence indicates synergy between oncogene and TGF beta signaling in epithelial cell transformation. This suggests opportunities for dissecting molecular mechanisms of cross-talk as well as providing insights into possible combinatorial molecular anticancer therapies that will include TGF beta inhibitors.

引用

页码：30 / 37

页数：8

共 61 条

[1]

Bandyopadhyay A, 2002, CANCER RES, V62, P4690

[2] Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J].